AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32997088 — intervention group
Group type: EXPERIMENTAL
Intervention: GT (glaze on tensile side)
Number of subjects: 80
Study 32997088 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC (glaze on both sides)
Number of subjects: 80
Study 32997088 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC-A (glaze on both sides, aged)
Number of subjects: 80
Study 32997088 — intervention group
Group type: COMPARATOR
Intervention: Control (no glazing)
Number of subjects: 80
Study 33875324 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Training (WT), two sessions/week, 15 cycles of two minutes walking at pain threshold intensity interspersed by two minutes of upright rest
Number of subjects: 32
Study 33875324 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Training (WT)
Number of subjects: 32
Study 33875324 — intervention group
Group type: COMPARATOR
Intervention: Control (CO), two sessions/week, 30 minutes of stretching
Number of subjects: 32
Study 35490603 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL drain removal
Number of subjects: 187
Study 35490603 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL drain removal
Number of subjects: 187
Study 35490603 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL drain removal
Number of subjects: 187
Study 34088920 — intervention group
Group type: COMPARATOR
Intervention: Regular calcium + 5 x 10^8 CFU/day L. casei CRL 431 (Casei)
Number of subjects: 238
Study 34088920 — intervention group
Group type: COMPARATOR
Intervention: Regular calcium + 5 x 10^8 CFU/day Lactobacillus reuteri DSM 17938 (Reuteri)
Number of subjects: 238
Study 34088920 — intervention group
Group type: COMPARATOR
Intervention: Low-lactose milk fortified with low levels of calcium (LC)
Number of subjects: 238
Study 34088920 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular levels of calcium (RC)
Number of subjects: 238
Study 35209942 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day probiotic cheese
Number of subjects: 40
Study 35209942 — intervention group
Group type: COMPARATOR
Intervention: Low-salt and low-fat cheese without any added probiotic
Number of subjects: 40
Study 32713421 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy after 6 weeks
Number of subjects: 7
Study 32713421 — intervention group
Group type: COMPARATOR
Intervention: CPAP titration
Number of subjects: 7
Study 34217036 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + FE
Number of subjects: 25
Study 34217036 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 25
Study 32555037 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty
Number of subjects: 0
Study 32555037 — intervention group
Group type: COMPARATOR
Intervention: Plate Fixation
Number of subjects: 0
Study 36102822 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 3718
Study 36102822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3718
Study 33966526 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support programme with telemonitoring
Number of subjects: 2607
Study 33966526 — intervention group
Group type: COMPARATOR
Intervention: Self-directed control arm
Number of subjects: 2607
Study 36089010 — intervention group
Group type: EXPERIMENTAL
Intervention: AUHII (Urban Heat Island Intensity)
Number of subjects: 86
Study 36089010 — intervention group
Group type: EXPERIMENTAL
Intervention: △AUHI (Change in Urban Heat Island Intensity)
Number of subjects: 86
Study 36089010 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRUMR (Urban minus Rural)
Number of subjects: 86
Study 36089010 — intervention group
Group type: EXPERIMENTAL
Intervention: CTROMR (Observation minus Reanalysis)
Number of subjects: 86
Study 36089010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling impact observed in some cities
Number of subjects: 86
Study 34309665 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (bevacizumab administered on the same day as chemotherapy)
Number of subjects: 230
Study 34309665 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (bevacizumab administered 4 days before chemotherapy)
Number of subjects: 230
Study 34309665 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 230
Study 34309665 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 230
Study 34464485 — intervention group
Group type: COMPARATOR
Intervention: Active frontopolar tDCS
Number of subjects: 24
Study 34464485 — intervention group
Group type: COMPARATOR
Intervention: Sham frontopolar tDCS
Number of subjects: 24
Study 33189161 — intervention group
Group type: EXPERIMENTAL
Intervention: SNG001 (6 MIU) inhaled daily for 14 days
Number of subjects: 101
Study 33189161 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled daily for 14 days
Number of subjects: 101
Study 34134824 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Body Checking (CBC)
Number of subjects: 142
Study 34134824 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Body Checking (NBC)
Number of subjects: 142
Study 34134824 — intervention group
Group type: COMPARATOR
Intervention: Non-Body Critical Checking (NBCC)
Number of subjects: 142
Study 36217132 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative exploration of perceived barriers to exclusive breastfeeding
Number of subjects: 30
Study 34642002 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise (PRO)
Number of subjects: 41
Study 34642002 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise (GEN)
Number of subjects: 41
Study 32375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened health management committees and community mobilisation through women's groups
Number of subjects: 13721
Study 32375684 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (22 clusters)
Number of subjects: 13721
Study 34863145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led sexual rehabilitation intervention
Number of subjects: 220
Study 34863145 — intervention group
Group type: COMPARATOR
Intervention: Optimal care as usual (CAU)
Number of subjects: 220
Study 35998039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (1000 mg) + Pterostilbene (200 mg)
Number of subjects: 32
Study 33871071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical and oral glutathione
Number of subjects: 46
Study 33871071 — intervention group
Group type: COMPARATOR
Intervention: Topical glutathione
Number of subjects: 46
Study 33871071 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 46
Study 34763847 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious exposure to spiders
Number of subjects: 98
Study 34763847 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible exposure to spiders
Number of subjects: 98
Study 34763847 — intervention group
Group type: COMPARATOR
Intervention: Unconscious exposure to flowers (control)
Number of subjects: 98
Study 34247632 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisolone (1 mg/kg/day)
Number of subjects: 96
Study 34247632 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prednisolone (0.5 mg/kg/day) and alfacalcidol (0.5 μg/day)
Number of subjects: 96
Study 33171595 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic plus biotin treatment
Number of subjects: 82
Study 33171595 — intervention group
Group type: COMPARATOR
Intervention: Biotin plus placebo
Number of subjects: 82
Study 32000408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried frailty scale
Number of subjects: 0
Study 32000408 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living scale (IADL)
Number of subjects: 0
Study 32000408 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 0
Study 32000590 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for atrial fibrillation after intracerebral hemorrhage
Number of subjects: 0
Study 32000590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulation)
Number of subjects: 0
Study 32000787 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain in adolescents
Number of subjects: 78
Study 32000787 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy as a mediator
Number of subjects: 78
Study 32000787 — intervention group
Group type: EXPERIMENTAL
Intervention: Future pain-management interventions
Number of subjects: 78
Study 32000810 — intervention group
Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination (prime-boost regimen with V935 and V934)
Number of subjects: 37
Study 32000810 — intervention group
Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination
Number of subjects: 37
Study 32000810 — intervention group
Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination in prostate cancer patients
Number of subjects: 37
Study 32000819 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession radiosurgery delivering 25 Gy in 5 daily fractions
Number of subjects: 0
Study 32002194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 0
Study 32002194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32002290 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-A2M4 T-cell therapy
Number of subjects: 0
Study 32002540 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 202
Study 32002540 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 202
Study 32002540 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and Epinephrine (multivariate model)
Number of subjects: 202
Study 32002540 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine and Norepinephrine
Number of subjects: 202
Study 32002821 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide and dexamethasone (D-Rd)
Number of subjects: 7
Study 32002847 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial blood flow (MBF) per-vessel
Number of subjects: 231
Study 32002847 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial flow reserve (MFR)
Number of subjects: 231
Study 32003099 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line insulin secretagogues (IS) or insulin
Number of subjects: 6217
Study 32003099 — intervention group
Group type: COMPARATOR
Intervention: No IS and insulin
Number of subjects: 6217
Study 32003749 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioral internet-delivered treatment
Number of subjects: 214
Study 32003749 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 214
Study 32004245 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP) activated ON at implant for patients with RV-to-LV delay less than 80 ms
Number of subjects: 248
Study 32004245 — intervention group
Group type: COMPARATOR
Intervention: Multipoint pacing (MPP) OFF for patients with RV-to-LV delay at least 80 ms
Number of subjects: 248
Study 32004245 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 248
Study 32004352 — intervention group
Group type: EXPERIMENTAL
Intervention: Next of Kin Participation in Care questionnaire (self-reported)
Number of subjects: 364
Study 32004497 — intervention group
Group type: EXPERIMENTAL
Intervention: Total screen viewing time (≥3 h per day)
Number of subjects: 552
Study 32004497 — intervention group
Group type: COMPARATOR
Intervention: Total screen viewing time (≤1 h per day)
Number of subjects: 552
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department (ED) visits
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admissions
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital days
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU days
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual costs for ICU admission
Number of subjects: 300
Study 32004554 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual costs for inpatient care
Number of subjects: 300
Study 32004908 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step nucleic acid amplification (OSNA)
Number of subjects: 26
Study 32004908 — intervention group
Group type: COMPARATOR
Intervention: Pathological analysis
Number of subjects: 26
Study 32005002 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK2 V617F positive ET
Number of subjects: 36
Study 32005002 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 32005112 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaires administered at three time points (t1, t2, t3)
Number of subjects: 2000
Study 32005159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural GPs
Number of subjects: 211
Study 32005159 — intervention group
Group type: COMPARATOR
Intervention: Urban GPs
Number of subjects: 211
Study 32005181 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene risk of recurrence signature (70-GS, MammaPrint)
Number of subjects: 358
Study 32005333 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered individual cognitive-behavioral therapy (CBT) for BDD
Number of subjects: 10
Study 32005489 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH) technique
Number of subjects: 33
Study 32005489 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH training and equipment
Number of subjects: 33
Study 32005489 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH compliance assessment
Number of subjects: 33
Study 32005489 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH technique feasibility
Number of subjects: 33
Study 32006121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic root replacement by graft
Number of subjects: 19
Study 32006348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 783
Study 32006348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 783
Study 32006348 — intervention group
Group type: COMPARATOR
Intervention: Observational comparison cohort (conventional synthetic DMARD, biologic DMARD, or apremilast)
Number of subjects: 783
Study 32006348 — intervention group
Group type: EXPERIMENTAL
Intervention: All-tofacitinib comparison cohort
Number of subjects: 783
Study 32006647 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe brachial index (TBI) tertile 1
Number of subjects: 741
Study 32006951 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 19
Study 32006951 — intervention group
Group type: EXPERIMENTAL
Intervention: MEG
Number of subjects: 19
Study 32006951 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MEG and fMRI
Number of subjects: 19
Study 32007132 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32007426 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin oral suspension (pediatric equivalent doses 2.5-10 mg) for 12 weeks followed by a fixed dose ≥40-week treatment period.
Number of subjects: 0
Study 32007598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alflutinib (20 mg, 40 mg, 80 mg, 160 mg, or 240 mg once daily)
Number of subjects: 130
Study 32007598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alflutinib (40-240 mg)
Number of subjects: 130
Study 32007598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alflutinib
Number of subjects: 130
Study 32008218 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics before chemotherapy
Number of subjects: 1446
Study 32008218 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics during chemotherapy
Number of subjects: 1446
Study 32008218 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 1446
Study 32008915 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index (AHI) ≥ 2
Number of subjects: 114
Study 32008915 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMR (CMR+)
Number of subjects: 114
Study 32008915 — intervention group
Group type: COMPARATOR
Intervention: Low CMR (CMR-)
Number of subjects: 114
Study 32008981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate and GABA levels in UHR individuals
Number of subjects: 122
Study 32008981 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 122
Study 32009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with radiation followed by veliparib and temozolomide (TMZ)
Number of subjects: 66
Study 32009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib with radiation
Number of subjects: 66
Study 32009165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 100
Study 32009165 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 100
Study 32009263 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaptivCRT (aCRT) ON
Number of subjects: 1814
Study 32009263 — intervention group
Group type: COMPARATOR
Intervention: Standard CRT
Number of subjects: 1814
Study 32009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing engagement activities for informed consent process
Number of subjects: 81
Study 32009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing engagement activities for experience of trial participation
Number of subjects: 81
Study 32009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing idea contest for fairness/reciprocity in HIV clinical trials
Number of subjects: 81
Study 32009824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 32010048 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32010057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-neuroendoscopic technique
Number of subjects: 0
Study 32010577 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI305
Number of subjects: 450
Study 32010577 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 450
Study 32010719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 0
Study 32010719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 0
Study 32010719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32010755 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage
Number of subjects: 0
Study 32010755 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32011475 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional magnetic resonance imaging (fALFF) in PI patients
Number of subjects: 30
Study 32011678 — intervention group
Group type: EXPERIMENTAL
Intervention: HANT archwires
Number of subjects: 31
Study 32011678 — intervention group
Group type: COMPARATOR
Intervention: SENT archwires
Number of subjects: 31
Study 32011909 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-Intense (3 hourly sessions per day/3 days per week)
Number of subjects: 12
Study 32011909 — intervention group
Group type: COMPARATOR
Intervention: SPT-T (1 hour-long session per day/3 days per week)
Number of subjects: 12
Study 32011914 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32012039 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-Delivered Pulmonary Rehabilitation Intervention
Number of subjects: 0
Study 32012106 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for UTUC (specific treatments not detailed)
Number of subjects: 2451
Study 32012106 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (observational study)
Number of subjects: 2451
Study 32012111 — intervention group
Group type: EXPERIMENTAL
Intervention: 2GETHER USA intervention (relationship education and HIV prevention program)
Number of subjects: 280
Study 32012111 — intervention group
Group type: COMPARATOR
Intervention: Control condition (existing public health practice)
Number of subjects: 280
Study 32012114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered cognitive behavioral therapy (CBT-AD) for adherence and depression; 8 sessions.
Number of subjects: 160
Study 32012114 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group).
Number of subjects: 160
Study 32012116 — intervention group
Group type: EXPERIMENTAL
Intervention: Medly (mobile phone-based telemonitoring system) in addition to standard of care
Number of subjects: 144
Study 32012116 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 144
Study 32012159 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration (HDF)
Number of subjects: 60
Study 32012159 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 60
Study 32012159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HDF and HD)
Number of subjects: 60
Study 32012214 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at 15 to 150 μg/kg IV once every 3 weeks (Q3W) or 50 μg/kg IV weekly.
Number of subjects: 35
Study 32012230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab only
Number of subjects: 154
Study 32012230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and lenalidomide/Revlimid®
Number of subjects: 154
Study 32012763 — intervention group
Group type: EXPERIMENTAL
Intervention: RGB-D camera measurements
Number of subjects: 30
Study 32013314 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547659
Number of subjects: 265
Study 32013314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 32013703 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine
Number of subjects: 6789
Study 32013707 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally Optimized Coronary Intervention (FCI) using an optical-sensor pressure wire
Number of subjects: 226
Study 32013865 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy approach (ZF)
Number of subjects: 1020
Study 32013865 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy approach (CF)
Number of subjects: 1020